Photodynamic treatment (ALA-PDT) suppresses the expression of the oncogenic Bcr-Abl kinase and affects the cytoskeleton organization in K562 cells

J Photochem Photobiol B. 2006 Jun 1;83(3):205-12. doi: 10.1016/j.jphotobiol.2006.01.003. Epub 2006 Feb 21.

Abstract

K562 is the chronic myelogenous leukemia (CML)-derived cell line that expresses high levels of chimeric oncoprotein Bcr-Abl. The deregulated (permanent) kinase activity of Bcr-Abl leads to continuous proliferation of K562 cells and their resistance to the apoptosis promotion by conventional drugs. The photodynamic treatment (PDT) based on the application of 5-aminolevulinic acid (ALA) and irradiation with blue light (ALA-PDT) resulted in the suppression of K562 cells proliferation. It was followed by a necrosis-like cell death [K. Kuzelová, D. Grebenová, M. Pluskalová, I. Marinov, Z. Hrkal, J. Photochem. Photobiol. B 73 (2004) 67-78]. ALA-PDT led to the perturbation of the Hsp90/p23 multichaperone complex of which the Bcr-Abl is the client protein. Bcr-Abl protein was suppressed whereas the bcr-abl mRNA level was not affected. Further on, we observed several changes in the cytoskeleton organization. We detected ALA-PDT-mediated disruption of filamental actin structure using FITC-Phalloidin staining. In connection with this we uncovered certain cytoskeleton organizing proteins involved in the cell response to the treatment. Among these proteins, Septin2, which plays a role in maintaining actin bundles, was suppressed. Another one, PDZ-LIM domain protein 1 (CLP36) was altered. This protein acts as an adaptor molecule for LIM-kinase which phosphorylates and thus inactivates cofilin. Cofilin was indeed dephosphorylated and could thus be activated and operate as an actin-depolymerizing factor. We propose the scheme of molecular response of K562 cells to ALA-PDT.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminolevulinic Acid / pharmacology*
  • Carrier Proteins / metabolism
  • Cell Death / drug effects
  • Cell Death / radiation effects
  • Cytoskeleton / drug effects*
  • Cytoskeleton / pathology
  • Cytoskeleton / radiation effects*
  • DNA-Binding Proteins / metabolism
  • Fluorescein-5-isothiocyanate
  • Fusion Proteins, bcr-abl
  • Gene Expression Regulation
  • HSP90 Heat-Shock Proteins / metabolism
  • Humans
  • K562 Cells / drug effects
  • K562 Cells / pathology
  • K562 Cells / radiation effects
  • LIM Domain Proteins
  • Light*
  • Lim Kinases
  • Membrane Proteins
  • Microfilament Proteins / metabolism
  • Molecular Chaperones / metabolism
  • Oncogene Proteins / metabolism
  • Phalloidine / chemistry
  • Photosensitizing Agents / pharmacology
  • Protein Kinases / physiology
  • Protein-Tyrosine Kinases / drug effects
  • Protein-Tyrosine Kinases / metabolism*
  • Protein-Tyrosine Kinases / radiation effects
  • RNA, Messenger / metabolism
  • Time Factors
  • Transcription Factors

Substances

  • Carrier Proteins
  • DNA-Binding Proteins
  • HSP90 Heat-Shock Proteins
  • LDB2 protein, human
  • LIM Domain Proteins
  • LMO1 protein, human
  • Membrane Proteins
  • Microfilament Proteins
  • Molecular Chaperones
  • Oncogene Proteins
  • PDZK1 protein, human
  • Photosensitizing Agents
  • RNA, Messenger
  • Transcription Factors
  • Phalloidine
  • Aminolevulinic Acid
  • Protein Kinases
  • Protein-Tyrosine Kinases
  • Fusion Proteins, bcr-abl
  • LIMK1 protein, human
  • Lim Kinases
  • Fluorescein-5-isothiocyanate